The first clinical gene therapy trial for WAS was carried out in Germany and useda gamma-retroviral vector to correct CD34+ cells from ten WAS patients, nine ofwhom showed significant increase of platelet counts and restoration of immuneresponses. Here, CD34 is linked to Wiskott-Aldrich syndrome.